Streetbeat News

Products Services

CYCC

CYCCP

Cyclacel Pharmaceuticals presented new clinical, pharmacokinetic, and pharmacodynamic data on their novel CDK2/9 inhibitor, fadraciclib, at the 2024 ASCO Annual Meeting. The data supports ongoing studies in patients with solid tumors and lymphoma.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:38 pm

AMD

ARM

IRBO

SPDW

Arm Holdings Plc (NASDAQ:ARM) stock is trading higher on Monday following a broader sector selloff on Friday due to U.S. government sanctions on the Middle East regarding AI chips. CEO Rene Haas expects 100 billion Arm devices to be AI-ready by the end of 2025. Analysts remain bullish on Arm, citing licensing interest and royalty as key growth drivers. Arm plans to debut its AI chip in 2025. Advanced Micro Devices, Inc (NASDAQ:AMD) hinted at launching next-gen AI PCs, sparking rivalry with Arm. Investors can gain exposure to Arm via iShares Robotics And Artificial Intelligence Multisector ETF (NYSE:IRBO) and SPDR Portfolio Developed World Ex-US ETF (NYSE:SPDW).

Portfolio Pulse from Anusuya Lahiri

June 03, 2024 | 12:38 pm

DELL

HPQ

NVDA

Dell Technologies Inc (NYSE:DELL) reported strong first-quarter revenue growth but disappointed Wall Street with low margins on AI servers, causing shares to drop. Despite surpassing revenue estimates, earnings lagged, and concerns were raised about the profitability of Dell's AI initiatives. HP Inc (NYSE:HPQ) also reported its fiscal second-quarter results, showing a slight decline in sales but an increase in earnings. Nvidia Corporation (NASDAQ:NVDA) was mentioned as a key partner for Dell's AI servers, with supply issues impacting Dell's performance.

Portfolio Pulse from Upwallstreet

June 03, 2024 | 12:37 pm

VLN

Valens Semiconductor (NYSE:VLN) has acquired Acroname for $7.8 million in cash, plus $1.3 million held by Acroname at closing. The acquisition aims to enhance Valens' position in the industrial market with a comprehensive USB-focused offering. The deal includes potential earn-out payments up to $7.2 million based on future performance targets.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:37 pm

VMAR

Vision Marine Technologies has filed its fifth patent on a vehicle control unit, which is expected to enhance the performance and safety of its electric boats.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:37 pm

LCID

TSLA

Portfolio Pulse from Anan Ashraf

June 03, 2024 | 12:36 pm

CORT

Corcept Therapeutics (NASDAQ:CORT) will present results from its Phase 3 GRACE trial evaluating relacorilant in patients with hypercortisolism at the ENDO 2024 and HiD conferences.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:36 pm

KTRA

TuHURA Biosciences and Kintara Therapeutics announced positive Phase 1b trial results for IFx-2.0 in treating checkpoint inhibitor-resistant advanced Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma. The trial showed that IFx-2.0 was safe and well-tolerated, with 80% of ICI naïve patients achieving a durable response.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:36 pm

SPOT

Spotify has announced adjustments to its Premium subscription prices in the US. The new prices are: Individual $11.99, Duo $16.99, Family $19.99, and Student $5.99. This change aims to support continued investment and innovation in Spotify's product features.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:35 pm

BPTH

GME

NTLA

Market-Moving News for June 3rd includes significant updates for GameStop (GME), Bio-Path Holdings (BPTH), and Intellia Therapeutics (NTLA). 'Roaring Kitty' revealed a massive GME position, BPTH presented interim results from a Phase 2 study, and NTLA announced long-term data from a Phase 1/2 study.

Portfolio Pulse from ryanfaloona@benzinga.com

June 03, 2024 | 12:35 pm